Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Shares Outstanding (Diluted Average): 2020-2024

Historic Shares Outstanding (Diluted Average) for Intellia Therapeutics (NTLA) over the last 5 years, with Dec 2024 value amounting to $98.8 million.

  • Intellia Therapeutics' Shares Outstanding (Diluted Average) rose 9.09% to $110.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.2 million, marking a year-over-year increase of 9.09%. This contributed to the annual value of $98.8 million for FY2024, which is 11.35% up from last year.
  • Per Intellia Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $98.8 million for FY2024, which was up 11.35% from $88.8 million recorded in FY2023.
  • Over the past 5 years, Intellia Therapeutics' Shares Outstanding (Diluted Average) peaked at $98.8 million during FY2024, and registered a low of $56.0 million during FY2020.
  • In the last 3 years, Intellia Therapeutics' Shares Outstanding (Diluted Average) had a median value of $88.8 million in 2023 and averaged $88.2 million.
  • Data for Intellia Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY grew of 26.63% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Intellia Therapeutics' Shares Outstanding (Diluted Average) stood at $56.0 million in 2020, then grew by 26.63% to $70.9 million in 2021, then rose by 8.57% to $77.0 million in 2022, then climbed by 15.33% to $88.8 million in 2023, then climbed by 11.35% to $98.8 million in 2024.